Sets stage for advanced scientific discovery
of new diagnostic biomarkers and treatments for disease
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™ and
SkyWaterTechnology (NASDAQ: SKYT), the trusted technology
realization partner, announced today they will jointly expand their
relationship to support development of Proteus™, Quantum-Si’s
next-generation platform designed to transform proteomic research.
The expanded collaboration will develop the consumable for Proteus
that will enable simultaneous large factor, protein sequencing with
unparalleled accuracy.
Quantum-Si and SkyWater began partnering in 2021 on the
first-generation Platinum® platform and announced transition
to support production in the second quarter of 2024. SkyWater will
continue to supply the consumables for the Platinum Pro product as
the two companies expand their engagement to support
commercialization of Proteus.
This cutting-edge solution is set to redefine proteomics with
unprecedented output per sample, application flexibility and
automation. By combining Quantum-Si’s expertise in biotechnology
with SkyWater’s Technology as a Service (TaaS) manufacturing
capabilities, the collaboration is poised to drive significant
advancements in protein sequencing and to the field of
proteomics.
"We’re pleased to build on past success together and move into
this next product development program with momentum to drive the
innovations for this revolutionary proteomics platform," said Ross
Miller, SVP Commercial and A&D Business, SkyWater Technology.
"This collaboration underscores SkyWater’s commitment to enabling
transformative technologies that have the potential to reshape
industries and improve lives."
"We are excited to expand our relationship with SkyWater around
Platinum, and to apply the learnings and their unique capabilities
to our next platform innovation," said Jeff Hawkins, President and
CEO of Quantum-Si. "SkyWater’s manufacturing expertise and
commitment to innovation make them an ideal partner as we work to
commercialize this game-changing platform. With Platinum, we were
the first to bring Next-Generation Protein Sequencing™ to
researchers globally and we believe our new technology will enable
us to further extend our leadership position in protein sequencing
and allow us to extend our technology into other areas of
proteomics.”
Leveraging its custom process development and robust
manufacturing capabilities, SkyWater enables the unique
technological needs of microfluidic biomedical devices from proof
of concept to final qualification. Embracing a TaaS model, SkyWater
facilitates early collaboration with system engineers and device
designers, developing technology within a production environment.
This approach expedites time-to-market, ensures quality from
inception, and seamlessly scales to meet volume production
demands.
SkyWater holds certification to the ISO 13485 Quality Standard
for Medical Devices, affirming its ability to support the design,
development, and fabrication of biomedical applications.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
Platinum® instrument enables Next-Generation Protein Sequencing™
that advances proteomic research, drug discovery, and diagnostics
beyond what has been possible with existing proteomic tools. Learn
more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company’s expectations with respect to future performance and
development and commercialization of products and services, its
anticipated cash runway and its financial guidance for the full
year 2024. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from those discussed in the forward-looking
statements. Most of these factors are outside the Company’s control
and are difficult to predict. Factors that may cause such
differences include, but are not limited to: the inability to
maintain the listing of the Company’s Class A common stock on The
Nasdaq Stock Market; the ability of the Company to grow and manage
growth profitably and retain its key employees; the Company’s
ongoing leadership transitions; changes in applicable laws or
regulations; the ability of the Company to raise financing in the
future; the success, cost and timing of the Company’s product
development and commercialization activities; the commercialization
and adoption of the Company’s existing products and the success of
any product the Company may offer in the future; the potential
attributes and benefits of the Company’s commercialized Platinum®
protein sequencing instrument and kits and the Company’s other
products once commercialized; the Company’s ability to obtain and
maintain regulatory approval for its products, and any related
restrictions and limitations of any approved product; the Company’s
ability to identify, in-license or acquire additional technology;
the Company’s ability to maintain its existing lease, license,
manufacture and supply agreements; the Company’s ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company’s products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company’s estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company’s financial performance; and other risks and uncertainties
described under “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q and in the
Company’s other filings with the SEC. The Company cautions that the
foregoing list of factors is not exclusive. The Company cautions
readers not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. The Company does
not undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
About SkyWater Technology
SkyWater (NASDAQ: SKYT) is a U.S.-based semiconductor
manufacturer and a DMEA-accredited Category 1A Trusted Supplier.
SkyWater’s Technology as a Service model streamlines the path to
production for customers with development services, volume
production and heterogeneous integration solutions in its U.S.
facilities. This pioneering model enables innovators to co-create
the next wave of technology within diverse categories including
mixed-signal CMOS, read-out ICs, rad-hard ICs, MEMS,
superconducting ICs, photonics and advanced packaging. SkyWater
serves the growing markets of aerospace & defense, automotive,
biomedical, industrial and quantum computing. For more information,
visit: www.skywatertechnology.com.
SkyWater Technology Forward-Looking Statements
This press release contains “forward-looking” statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements that are based on the Company’s current
expectations or forecasts of future events, rather than past events
and outcomes, and such statements are not guarantees of future
performance. Forward-looking statements are subject to risks,
uncertainties and assumptions, which may cause the Company’s actual
results, performance or achievements to be materially different
from those expressed or implied by such forward-looking statements.
Key factors that could cause the Company’s actual results to be
different than expected or anticipated include, but are not limited
to, factors discussed in the “Risk Factors” section of its annual
report on Form 10-K and quarterly reports on Form 10-Q, and in
other documents that the Company files with the SEC, which are
available at http://www.sec.gov. The Company assumes no obligation
to update any forward-looking statements, which speak only as of
the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241120350902/en/
Quantum-Si Investor Contact Doug Farrell, VP, Investor
Relations ir@quantum-si.com
Quantum-Si Media Contact Katherine Atkinson, SVP,
Commercial Marketing media@quantum-si.com
SkyWater Company Contact: Tara Luther, Director of
Corporate Communications tara.luther@skywatertechnology.com
SkyWater Media Contact: Lauri Julian, Public Relations
Strategist lauri.julian@skywatertechnology.com
SkyWater Technology (NASDAQ:SKYT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
SkyWater Technology (NASDAQ:SKYT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
